Ocugen Delays Vote Again On Adding 250 Million Authorized Shares
The board backs the proposal unanimously, while broker-held shareholders face a warning about relying on earlier voting instructions.
Ocugen, which develops gene therapies for blinding eye diseases, has again postponed the vote on authorizing 250 million additional common shares, according to Friday's additional proxy filing describing the renewed postponement. The proposal remains unresolved after earlier adjournments intended to give shareholders more time to consider it and vote.
Authorization, Not Shares Already Issued
Proposal 1 would change Ocugen's corporate charter to permit 250,000,000 more common shares. The board unanimously recommends approval; the request concerns permission to issue shares, rather than an issuance itself.
Ocugen had 339,306,603 shares issued and outstanding on October 30, 2026. That existing share count provides the scale of the authorization request, but authorized shares and outstanding shares are different measures.
The special meeting originally convened on September 21, 2026, when shareholders approved allowing an adjournment. The meeting moved to October 5, 2026, solely for the share proposal, and was then adjourned to October 26, 2026.
Earlier Votes May Need Renewing
For registered shareholders eligible to vote, Ocugen intends to reuse previously submitted proxies that have not been revoked. Those votes will follow the holder's instructions; a proxy without a specified direction will count in favor of Proposal 1.
Holders whose shares sit with a bank, broker or other nominee face a different mechanic. Ocugen intends to ask those intermediaries to follow earlier voting instructions, but cautions that it cannot guarantee they will do so without a new instruction form. Holders should check with their intermediary about whether the previous instructions remain effective.
Registered holders can change or revoke an earlier proxy through a later proxy card, a new telephone or internet submission, written notice to the corporate secretary, or a vote during the reconvened meeting.
Eye Therapies Lead The Pipeline
Ocugen's central development approach delivers genes called nuclear hormone receptors to the retina through its modifier gene therapy platform. Its lead candidate, OCU400, targets retinitis pigmentosa, an inherited disease that damages retinal cells, and has completed enrollment of 140 participants in a late-stage trial.
Other candidates include OCU410 for geographic atrophy, an advanced form of dry age-related macular degeneration, and OCU410ST for Stargardt disease. The company's early programs also span a protein drug for diabetic eye disease, a knee cartilage cell therapy through subsidiary OrthoCellix, and inhaled COVID-19 and flu vaccines.
Shareholders are scheduled to decide the share-authorization proposal at the reconvened special meeting on December 22, 2026.
Sources
- Ocugen — DEFA14A (2026-11-06) — SEC EDGAR
- Ocugen's Q3 Earnings Match Estimates, Revenues Beat, Stock Rises — Yahoo Finance
- Ocugen, Inc. Q3 2026 Earnings Call Summary — Yahoo Finance
- Ocugen (OCGN) Reports Q3 Loss, Tops Revenue Estimates — Yahoo Finance
- Ocugen: Q3 Earnings Snapshot | khou.com — Associated Press
- Ocugen Provides Business Update with Third Quarter 2026 — globenewswire.com
